Manipal Health Enterprises promoters encumber 21.78% stake for term loan
Deutsche Bank AG disclosed that 286,443,818 shares of Manipal Health Enterprises Limited, held by promoter entities Manipal Global Health Services, Cypress Holdings, and MRMSI, have been encumbered. This represents 21.78% of the issued capital and 21.50% on a diluted basis. The encumbrance serves as security for a term loan facility, involving indirect charges created by parent companies MEMG International Ltd and Manipal Global Health Services in May and July 2025.

*this image is generated using AI for illustrative purposes only.
Deutsche Bank AG, Singapore Branch, acting as agent and offshore security agent, disclosed the creation of an encumbrance over a significant portion of manipal health enterprises limited 's promoter-held equity shares. The disclosure, filed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, reveals that 286,443,818 shares are now encumbered, representing 21.78% of the issued and paid-up share capital and 21.50% on a fully diluted basis. This move secures a term loan facility for key promoter entities, impacting the liquidity and transferability of these stakes.
The encumbrance stems from a facility agreement dated May 20, 2025, entered into by Manipal Global Health Services ("Borrower 1") and Cypress Holdings ("Borrower 2"). Deutsche Bank AG, Singapore Branch, acts as both the Agent and the Offshore Security Agent for the lenders. Axis Trustee Services Limited, Gift City Branch, serves as the Onshore Security Agent. The charges were created to secure the term loan facility availed by the Borrowers.
The structure involves indirect charges over the target company's shares through parent entities. MEMG International Ltd ("MEMGI"), the parent of Borrower 1, created a charge on 100% of Borrower 1's share capital via a deed dated May 22, 2025. Similarly, Borrower 1 created a charge on 100% of Borrower 2's share capital via a deed dated July 2, 2025. Additionally, MEMGI created a charge on 100% of Manipal Research & Management Services International ("MRMSI")'s share capital on May 22, 2025. These actions result in indirect charges over the shares held by these entities in Manipal Health Enterprises Limited.
| Entity | Shares Held | % of Issued Capital | Charge Date | Nature of Charge |
|---|---|---|---|---|
| Manipal Global Health Services | 232,147,755 | 17.65% | May 22, 2025 | Indirect (via MEMGI) |
| Cypress Holdings | 49,172,520 | 3.74% | July 2, 2025 | Indirect (via Borrower 1) |
| MRMSI | 5,123,543 | 0.39% | May 22, 2025 | Indirect (via MEMGI) |
| Total Encumbered | 286,443,818 | 21.78% | N/A | Indirect & Covenants |
In addition to the fixed and floating charges, the Borrowers provided covenants in favor of the Agent and Offshore Security Agent regarding the equity shares held by them and MRMSI. These covenants constitute encumbrances covering 21.50% of the share capital on a fully diluted basis, including employee stock option plan pool options outstanding. The disclosure treats these encumbrances as an acquisition under Regulation 29(1) read with Regulation 29(4) of the Takeover Code.
What the Numbers Show
The encumbrance covers the entire shareholding of the three key promoter entities mentioned: Manipal Global Health Services, Cypress Holdings, and MRMSI. With 21.78% of the total voting power now pledged, any default on the term loan could lead to a change in control or significant dilution of promoter interests. The use of indirect charges through parent companies (MEMGI and Borrower 1) suggests a structured financing arrangement designed to secure debt while maintaining operational control at the subsidiary level until potential distress events occur. The total diluted holding remains unchanged at 1,332,067,702 shares, indicating no new issuance but rather a restriction on existing float.
Historical Stock Returns for Manipal Health Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.66% | +14.15% | +14.15% | +14.15% | +14.15% | +14.15% |
How might the encumbrance of 21.78% of promoter-held equity impact Manipal Health's credit rating and future cost of capital?
What are the specific financial covenants attached to this term loan, and how close is the company to breaching them given current market conditions?
Could this pledge trigger a forced sale or change in control if the share price declines significantly, and what safeguards exist for minority shareholders?






























